Skip to main content

Brittany Henderson, MD

Brittany Henderson, MD

Medical Director and Head Physician
Charleston Thyroid Center
Mount Pleasant, South Carolina

Related Videos

Given your practice focus and experience, can you discuss the disease burden of hypothyroidism, the spectrum of the disease, treatment options, and how DTE formulations differ in terms of T4 and T3 composition?

Given your practice focus and experience, can you discuss the disease burden of hypothyroidism, the spectrum of the disease, treatment options, and how DTE formulations differ in terms of T4 and T3 composition?

Given your practice focus and experience, can you discuss the disease burden of hypothyroidism, the spectrum of the disease, treatment options, and how DTE formulations differ in terms of T4 and T3 composition?

Can you discuss initiating and sequencing thyroid hormone replacement—how you monitor patients, guideline-directed therapy, and the importance of metabolic and patient-centric factors in determining when DTE therapy should be considered?

Can you discuss initiating and sequencing thyroid hormone replacement—how you monitor patients, guideline-directed therapy, and the importance of metabolic and patient-centric factors in determining when DTE therapy should be considered?

Can you discuss initiating and sequencing thyroid hormone replacement—how you monitor patients, guideline-directed therapy, and the importance of metabolic and patient-centric factors in determining when DTE therapy should be considered?

What are the clinical triggers—among them, lack of symptom control, inability to achieve normalization of thyroid hormone function biomarkers/tests, treatment failure with T4, and metabolic co-morbidities affecting T4-to-T3 conversion—that prompt you to consider a person an ideal candidate for DTE-based hormone replacement?

What are the clinical triggers—among them, lack of symptom control, inability to achieve normalization of thyroid hormone function biomarkers/tests, treatment failure with T4, and metabolic co-morbidities affecting T4-to-T3 conversion—that prompt you to consider a person an ideal candidate for DTE-based hormone replacement?

What are the clinical triggers—among them, lack of symptom control, inability to achieve normalization of thyroid hormone function biomarkers/tests, treatment failure with T4, and metabolic co-morbidities affecting T4-to-T3 conversion—that ...

Can you summarize what the current evidence, expert opinion, and clinical experience has taught us, and how it should guide us, in terms of identifying persons with hypothyroidism who should be considered for DTE-based hormone replacement therapy?

Can you summarize what the current evidence, expert opinion, and clinical experience has taught us, and how it should guide us, in terms of identifying persons with hypothyroidism who should be considered for DTE-based hormone replacement therapy?

Can you summarize what the current evidence, expert opinion, and clinical experience has taught us, and how it should guide us, in terms of identifying persons with hypothyroidism who should be considered for DTE-based hormone replacement therapy?

What persistent hypothyroid-related symptom do you look for to suggest T4 monotherapy may not be the optimal approach?

What persistent hypothyroid-related symptom do you look for to suggest T4 monotherapy may not be the optimal approach?

What persistent hypothyroid-related symptom do you look for to suggest T4 monotherapy may not be the optimal approach?

Once you or any clinician has determined that DTE may be an appropriate treatment approach for a patient with hypothyroidism, how do you transition the patient from T4 to DTE, and what should the thyroid function monitoring strategy be for patients who have been started on DTE?

Once you or any clinician has determined that DTE may be an appropriate treatment approach for a patient with hypothyroidism, how do you transition the patient from T4 to DTE, and what should the thyroid function monitoring strategy be for patients who have been started on DTE?

Once you or any clinician has determined that DTE may be an appropriate treatment approach for a patient with hypothyroidism, how do you transition the patient from T4 to DTE, and what should the thyroid function monitoring strategy be ...

Can you please let us know a little bit about yourself, including your previous affiliations and experience treating patients with thyroid disease, especially hypothyroidism?

Can you please let us know a little bit about yourself, including your previous affiliations and experience treating patients with thyroid disease, especially hypothyroidism?

Can you please let us know a little bit about yourself, including your previous affiliations and experience treating patients with thyroid disease, especially hypothyroidism?

What are the trials, patient preference studies, and other evidence supporting your approach for deploying DTE in clinically appropriate populations, and in what percentage of patients with hypothyroidism does DTE become the treatment modality of choice?

What are the trials, patient preference studies, and other evidence supporting your approach for deploying DTE in clinically appropriate populations, and in what percentage of patients with hypothyroidism does DTE become the treatment modality of choice?

What are the trials, patient preference studies, and other evidence supporting your approach for deploying DTE in clinically appropriate populations, and in what percentage of patients with hypothyroidism does DTE become the treatment modality of choice?